The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma
Business Of Biotech
00:00
Biotech Accelerator - C Y T I v a Life Sciences
The cost really becomes the issue for a lot of early face LNG therapy companies it's speed to market, right. So I think speed is probably the more critical decision than cost for a board when looking to make decisions on internal versus external. Check out a host of useful resources for biotech leaders at siteiva's emerging biotech accelerator at siteiva life sciences.com backslash emerging biotech.
Transcript
Play full episode
